NasdaqGM - Nasdaq Real Time Price USD

MediWound Ltd. (MDWD)

13.30 -0.56 (-4.04%)

At close: October 30 at 4:00:01 PM EDT

13.30 -0.03 (-0.23%)

After hours: October 30 at 4:00:05 PM EDT

Trade MDWD on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for MDWD

Previous Close 13.86
Open 13.94
Bid 10.22 x 200
Ask 18.25 x 200
Day's Range 13.24 - 13.94
52 Week Range 11.80 - 19.70
Volume 110,105
Avg. Volume 94,275
Market Cap (intraday) 171.707M
Beta (5Y Monthly) 0.09
PE Ratio (TTM) --
EPS (TTM) -2.08
Earnings Date Nov 12, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 30.67
Motley Fool Rating Bearish

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

www.mediwound.com

121

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MDWD

27.95%

S&P 500 (^GSPC)

10.73%

1-Year Return

MDWD

28.30%

S&P 500 (^GSPC)

11.11%

3-Year Return

MDWD

62.20%

S&P 500 (^GSPC)

81.91%

5-Year Return

MDWD

46.02%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q1 FY26

Revenue 1.48M

Earnings -2.95M

Profit Margin -200.14%

FY25

FY26

-10M

-5M

-300.0%

-200.0%

-100.0%

Analyst Price Targets

25.00

30.67 Average

13.30 Current

36.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 8/14/2026

Analyst Oppenheimer

Rating Action Maintains

Rating Outperform

Price Action Lowers

Price Target 32 -> 30

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

-170.10%
Return on Assets (ttm)

-28.59%
Return on Equity (ttm)

-72.37%
Revenue (ttm)

11.86M
Net Income Avi to Common (ttm)

-20.18M
Diluted EPS (ttm)

-2.08

Balance Sheet and Cash Flow

Total Cash (mrq)

35.34M
Total Debt/Equity (mrq)

24.14%
Levered Free Cash Flow (ttm)

-29.05M

KMDA Kamada Ltd.

7.70 -3.14%

EOCN Eocene Ltd.

3.1000 -3.73%

URGN UroGen Pharma Ltd.

32.72 -2.27%

SLGL Sol-Gel Technologies Ltd.

68.35 -0.45%

CLGN CollPlant Biotechnologies Ltd.

4.1350 -6.02%

U.S. markets closed

MediWound Ltd. (MDWD)

Trading disclosure

10.83%

-3.41%

-19.39%

-27.95%

-28.30%

-46.02%

-88.12%

MediWound Ltd. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch